

REVIEW

Screening for coeliac disease in type 1 diabetes

G K T Holmes

Arch Dis Child 2002;**87**:495–499

The average prevalence of coeliac disease among children with diabetes mellitus in 26 reports was 4.5% (0.97–16.4%). Malabsorption, unstable diabetes, and growth failure, indicate that coeliac disease may be present. Even those who are apparently asymptomatic may have subtle complaints indicative of coeliac disease if a careful history is taken. Ill health may only be recognised in retrospect following the benefits conferred by a gluten free diet. For these reasons it is recommended that a screening programme should be instituted to detect coeliac disease in these children. Parents and where possible children themselves, should be fully involved at all stages of the screening, diagnostic, and treatment process.

and jejunal biopsies carried out in six showed villous atrophy. In these six, control of diabetes was poor, and in five, hypoglycaemic convulsions frequently occurred. Adherence to GFD was poor. A screening study of 215 children with diabetes found that nine had ARA in the serum, all of whom had small intestinal biopsy specimens taken.⁸ Four new cases of CD were found, and as one was already known in the group the prevalence was 1:43. None of these children had diarrhoea or symptoms of malabsorption but did have some symptoms that could be attributed to CD. Since then, many screening studies have been carried out in children, yielding a prevalence of CD between 0.97 and 16.4% (table 1).^{8–33} With regard to the last figure, it is of interest that coeliac disease is very common among children from the Sahara, with 5–6% affected.³⁴

The increased prevalence of CD in type 1 diabetes can partly be explained by the presence of the common HLA markers B8 and DR3^{9 11 12} and the DQB1*0201 allele that encodes a particular heterodimer.^{17 19} It is also of interest that diabetes related autoantibodies may be present in a quarter of patients with CD and may predict the future development of CD.³⁵

SCREENING FOR COELIAC DISEASE IN DIABETES

As CD is so common in type 1 diabetes, the question arises as to whether this group should be screened routinely for this disorder. It is noteworthy that many workers already advocate routine screening in children.^{8 12 15 17–19 21 23 26 27 30 31 33} However, there are a number of points that require consideration. Will health benefits accrue to this group in terms of resolution of symptoms, a reduction in complications associated with coeliac disease, and improved control of diabetes if given a GFD? Will patients comply with a GFD? Is one test enough, and if not, when should subsequent tests be carried out? Is a screening programme cost effective when compared with other such programmes?

PRESENTATION

In about 90% of patients diabetes is diagnosed before CD.³⁶ In the various reports the numbers of patients with symptoms and signs differ widely, which probably reflects how carefully these were sought. It is likely that some patients were regarded as asymptomatic when they were not.

Coeliac disease (CD) is now one of the commonest chronic disorders encountered in the western world, with a prevalence as high as 1.3% in recent screening studies in children.¹ The advent of serological tests that measure antigliadin (AGA), antireticulin (ARA), antiendomysial (AEA), and antitissue transglutaminase (AtTG) antibodies has greatly aided the diagnosis. In terms of sensitivity and specificity the latter two investigations are preferred. It should be stressed that a small intestinal biopsy is still necessary to confirm the diagnosis. Many disorders have been found in association with CD, but the majority are chance occurrences.² However, type 1 diabetes mellitus and thyroid disease, and some other conditions with a possible immunological aetiology, occur more commonly than by chance alone. Type 1 diabetes mellitus is the commonest and best researched associated condition and the question addressed in this article is whether screening for CD in type 1 diabetes mellitus should become routine in paediatric practice. An article that relates to adults is available.³

COELIAC DISEASE AND DIABETES

The association of childhood diabetes mellitus and CD was first reported over 40 years ago.^{4 5} In an early clinical investigation of 400 children with diabetes mellitus, six were found to have CD on small intestinal biopsy. All presented with classical symptoms and improved on a gluten free diet (GFD) with fewer hypoglycaemic episodes.⁶ The authors commented that the diagnosis of CD was sometimes delayed because of the preoccupation with diabetes. Among 300 children with diabetes, eight had symptoms of CD with stunted growth.⁷ All had steatorrhoea,

See end of article for author's affiliation

Correspondence to:
Dr G K T Holmes,
Consultant
Gastroenterologist,
Department of Medicine,
Derbyshire Royal Infirmary,
London Road, Derby
DE1 2QY, UK;
GeoffreyHolmes@
compuserve.com

Accepted 25 July 2002

Abbreviations: AEA, antiendomysial antibodies; AGA, antigliadin antibodies; ARA, antireticulin antibodies; AtTG, antitissue transglutaminase antibodies; CD, coeliac disease

Table 1 Prevalence of coeliac disease in diabetes mellitus found in screening studies in children

Ref.	Year	Country	No.	Screen	+ve screen	No. biopsied	CD by biopsy	Prevalence
8	1984	Finland	215	ARA	9	9	4 (+1)	1:43 2.3%
9	1986	Finland	201	AGA	–	–	7	1:29 3.5%
10	1987	Italy	146	AGA	9	9	5	1:29 3.4%
11	1988	Germany	1032	AGA	17	9	2 (+8)	1:103 0.97%
12	1991	Italy	498	AGA	30	22	16	1:31 3.2%
13	1992	Australia	180	AGA	19	18	4	1:45 2.2%
14	1993	Sweden	436	AGA	28	26	15 (+6)	1:21 4.8%
15	1993	USA	211	AEA	10	3	3	1:70 1.4%
16	1994	Australia	273	AEA	5	5	5	1:55 1.8%
17	1996	Finland	776	AGA	36	19	19	1:41 2.4%
18	1996	Italy	133	AGA	6	6	5	1:27 3.7%
19	1996	Italy	172	AGA	7	7	6	1:29 3.5%
20	1996	Algeria	116	AGA	13	13	16* (+3)	1:6 16.4%
21	1996	Spain	141	AGA	12	12	4 (+2)	1:24 4.2%
22	1997	Italy	200	AGA	14	11	8	1:25 4.0%
23	1998	Canada	236	AEA	19	17	12	1:20 5.0%
24	1998	UK	167	AEA	11	9	8	1:21 4.8%
25	1998	Spain	93	AEA	7	7	6	1:16 6.45%
26	1998	Spain	177	AEA	–	–	3 (4)	1:25 4.0%
27	1999	Sweden	115	AEA	9	6	5 (+2)	1:16 6.2%
28	2000	Austria	403	AEA	14	13	6	1:67 1.5%
29	2000	Germany	520	AiTG	23	13	9	1:58 1.7%
30	2001	Canada	233	AEA	19	18	14 (+4)	1:13 7.7%
31	2001	USA	218	AEA	17	14	10	1:22 4.6%
32	2001	Denmark	106	AGA	10	9	9 (+2)	1:10 10%
33	2002	Italy	274	EMA	27	20	16 (+1)	1:16 6.2%

*Three patients with negative serology biopsied on clinical grounds and all had coeliac disease. Numbers in brackets indicate patients with coeliac disease diagnosed before screening.

Furthermore, ill health may only be recognised retrospectively, following the benefits conferred by adopting a GFD. This is well illustrated in the following instance. A child of 5 years was diagnosed with diabetes, and at the age of 9 a screening test for CD was positive; the diagnosis was confirmed by a small intestinal biopsy. He had not gained weight in the previous year but his parents considered him to be asymptomatic. I quote with permission from a letter that his mother sent me.

“We did not consider that he had any of the symptoms indicating coeliac disease, but decided to put him onto a GFD to see what would happen, and in fact there have been notable improvements. He was growing at an apparently normal rate before the GFD, but has grown notably in the five months since the diet was started. He has also put on weight and his diabetic control, while never too bad, has improved, particularly when we look at his HbA1c results over the past three months. Another unlooked for but welcome effect has been improved serenity in his general demeanour. He has always been a happy go lucky and cheerful boy, but in the past year we had noticed that he was becoming increasingly irritable. We had put this short temperedness down to his frustration with his diabetes and also considered it to be a product of his growing

up. However, following the GFD he has reverted to his former happy self. We are managing the diet very well at home and his school has been extremely supportive and provided excellent alternative school lunches for him. Thus, although my initial inclination was to leave well alone we are glad that we did begin following the GFD.”

Examples like this are plentiful and caution against readily labelling patients as asymptomatic when they are not.

At the time of screening, most children do not complain of gastrointestinal disturbances,^{8–11 13 15 16 18 21 22 26 29 31 33} but failure to thrive^{24 31} and gastrointestinal symptoms^{14 24 26 30–33} may be present, and in some cases may only be recognised in retrospect.^{14 24} Short stature has been reported in about one third of children,^{12 19 36} but in some series is not a feature.^{15 23 37} Delayed puberty may occur,^{8 19} and hypertransaminasaemia,^{19 30 32 38} anaemia,^{30 32} iron deficiency,^{19 33} arthralgia,^{8 19} dental enamel defects,³² hypoglycaemia, and a reduction of insulin requirements³⁹ may indicate the presence of coeliac disease in children. Children with CD and diabetes are younger at the onset of diabetes than those without CD,^{11 32} but this has been disputed.³³

VALUE OF A GLUTEN FREE DIET

Features of coeliac disease

A GFD dramatically improves the great majority of patients with CD, and this also prevails in those with associated diabetes. Improvement has been noted in symptoms,^{14 24 31 33} with a sense of improved wellbeing and vitality, growth in children,^{18 19} serum antibody levels,^{8 10 14 19 24 27} haemoglobin concentration and mean red cell volume,³³ and in the architecture of the small intestinal mucosa.^{8 9 13 14 24}

Control of diabetes

In early clinical studies, CD was diagnosed in patients with diabetes because they had malabsorption. When this was corrected by adopting a GFD, diabetic control usually improved, with a reduction in hypoglycaemic episodes.⁶ In patients detected by screening, the influence of a GFD on diabetic control as judged by insulin requirements and glycosylated haemoglobin has been variable. Some report no effect,^{9 13 24 28 37} or improved control^{13 21} with less hypoglycaemic episodes.^{14 19 39} In some cases adherence to a GFD was not strict, making a proper assessment difficult.

Complications and associations

Adult CD is associated with a number of complications, the most serious of which is lymphoma.^{40 41} It has been shown that a strict GFD taken for at least five consecutive years protects against the development of this malignancy.⁴¹ While lymphoma is reported to occur in children with CD, it is extremely rare.⁴² In some adults the onset of lymphoma precipitates the diagnosis of CD; prior to this event, CD was latent or silent.⁴³ It could be argued that an earlier screened diagnosis of CD and treatment with a GFD might have prevented the onset of lymphoma. Lymphoma has been found in association with type 2 diabetes in some studies,⁴⁴⁻⁴⁶ but not others.⁴⁷ Of four patients with type 1 diabetes, two had enteropathy associated T cell lymphoma.⁴⁸ Investigations to determine causes of death in diabetes are difficult to carry out, and it may well be that more are dying of lymphoma than presently thought. This area requires further exploration.

Osteoporosis is another important occurrence in CD, but it is not clear how this translates into fracture risk. Children with CD may also be affected by osteoporosis. It is improved by a GFD. A reduction of bone mineral density is a feature of diabetes, particularly type 1,^{49 50} and predisposes to low energy fractures.⁵⁰ It has been suggested that CD should be considered a possible cause of osteopenia in type 1 diabetic patients found to have a reduced bone mineral density.⁵¹ Lymphoma and osteoporosis may affect asymptomatic coeliac patients.⁴⁰

Other health risks in CD include neurological disorders, epilepsy, and problems associated with reproduction—in particular, late menarche and early menopause, infertility, miscarriages, and low birthweight babies. A GFD may have a beneficial effect on some of these disorders and it could be argued that the earlier the detection and treatment of CD, the better for the patient in this regard.

An increased prevalence of autoimmune disorders occurs in patients with CD,^{52 53} and evidence exists to show that the longer the exposure to gluten in patients with CD, the more likely is the development of autoimmune diseases.⁵² The corollary of this is that a GFD might protect against the development of these disorders, perhaps by clearing certain autoantibodies, for example, those which are thyroid related, from the circulation.⁵⁴

EXPRESSIONS OF COELIAC DISEASE AND IMPLICATIONS FOR SCREENING STRATEGIES

With expanding knowledge of the natural history of CD it has become recognised that gluten sensitivity is wider than previously thought, and incorporates latent and potential CD.⁵⁵ Latent CD is defined by a normal biopsy in patients taking a

normal diet who, at some other time, before or since, have had a flat biopsy that recovers on a GFD. Before these patients develop a flat biopsy they have the potential to do so, and hence the term “potential coeliac disease” was proposed to define this phase of the disorder. In potential CD the upper small intestinal mucosa has normal looking villi, but subtle changes are present such as an increased number of intraepithelial lymphocytes bearing the $\gamma\delta$ T cell receptor and aberrant HLA-DR expression in the crypts. AEA may be present and in time the mucosa may become flat.⁵⁶ Patients with diabetes may have potential or latent CD,^{22 26 28 30 31 33 57} and this has implications for screening strategies.

Coeliac disease was searched for at the diagnosis of diabetes, and at 6, 12, 18, 24, and 36 months, and thereafter among 776 children with diabetes by the detection of AGA and ARA.¹⁷ At the diagnosis of diabetes, CD was confirmed in nine serologically positive patients by small intestinal biopsy. Nine who were serologically negative developed antibodies within two years and had CD confirmed by biopsy. Others have drawn attention to the importance of serial screening but it is uncertain what the time interval between tests should be. Some have supported screening at the diagnosis of diabetes and then annually.^{19 27 33} Others favour screening at diagnosis, and then at 1, 3, and 5 years.¹⁷ It has also been advocated that screening should be carried out 1–2 years after the diagnosis of diabetes to allow the tests to become positive.^{11 23} AGA may be present as a transient phenomenon at the onset of diabetes and may just reflect disturbed immunity or an increase in intestinal permeability at this time.^{11 22 26 27 32 58-60} AEA may also occur transiently.³³ Until more information becomes available, one strategy would be to screen at the diagnosis of diabetes and annually for three years, then at 5 years, and then five yearly thereafter or at any other time if there are clinical indications.

It has been suggested that screening should be offered to first degree relatives of those with type 1 diabetes because they frequently have silent CD.^{53 61} Those relatives with the HLA DRB1*03 DQA1*05 DQB1*02 (DR3-DQ2) haplotype require particular attention because AtTG and AEA were more prevalent in this subgroup. Others have also focused attention on those first degree relatives with the DQB1*02 allele.⁶²

COST OF A SCREENING PROGRAMME

Assuming a prevalence in the general population of type 1 diabetes of 0.4%, then for a hospital serving a population of 500 000 there would be 2000 existing patients. If these were screened at 1, 5, and 10 years, it can be calculated that the cost per case diagnosed would be £860, assuming that a serological test costs about £10 and a diagnostic upper gastrointestinal endoscopy £280. The incidence of type 1 diabetes in the UK is about 15–20 per 100 000 new cases per year. Based on the lower figure, 75 new cases would occur in a population of 500 000. If these were screened at diagnosis and 1, 2, 3, 5, and 10 years over a decade, the cost per case would be £950. Screening type 1 diabetics over the subsequent decades would incur similar costs. These expenses should be set against expenditure on unnecessary investigations, treatments, clinic visits, and admissions for those with type 1 diabetes who are ill with unrecognised coeliac disease as well as the consequences to health and wellbeing. These costs compare very favourably against other well established screening programmes; for example, for congenital hypothyroidism the median cost per true case has been estimated at £14 960, for cystic fibrosis £4500, and for phenylketonuria £25 000.⁶³

CONCLUSIONS

In children CD and type 1 diabetes mellitus are frequently associated. Malabsorption, unstable diabetes, and growth failure indicate the possible presence of CD. Even those who are thought to be asymptomatic may have subtle complaints such

as gastrointestinal upsets if a careful history is elicited. It is important to understand that in some, ill health may only be recognised in retrospect following the benefits conferred by a GFD.

A screening programme for CD is preferable to a case finding approach, because of the high prevalence of coeliac disease in type 1 diabetes, and ensures all cases would eventually be identified.

Parents and children themselves if possible, should receive a full explanation of the case for screening. Those who give consent to be tested would then, if found to have CD, be in a position to make informed choices about how they would like to proceed. Some will want to start a GFD and should be introduced to a sympathetic dietician skilled in managing diabetic and gluten free diets. Some who are serologically positive may not wish a confirmatory small bowel biopsy, while some who do have CD confirmed may not accept a GFD. Such patients could then be monitored carefully for the appearance of symptoms of anaemia, deficiencies of folate, iron, or calcium, growth failure, or unexplained difficulties in achieving control of diabetes, in which case prompt action could be taken.

Author's affiliation

G K T Holmes, Department of Medicine, Derbyshire Royal Infirmary, Derby, UK

REFERENCES

- Carlsson AK, Axelsson IE, Borulf SK, *et al.* Serological screening for coeliac disease in healthy 2.5-year-old children in Sweden. *Pediatrics* 2001;**107**:42–5.
- Collin P, Reunala T, Pukkala E, *et al.* Coeliac disease—associated disorders and survival. *Gut* 1994;**35**:1215–18.
- Holmes GKT. Coeliac disease and type 1 diabetes mellitus—the case for screening. *Diabet Med* 2001;**18**:169–77.
- Walker-Smith JA, Grigor, W. Coeliac disease in a diabetic child [letter]. *Lancet* 1969;**1**:1029.
- Visakorpi JK. Diabetes and coeliac disease [letter]. *Lancet* 1969;**2**:1192.
- Thain ME, Hamilton JR, Ehrlich RM. Coexistence of diabetes mellitus and coeliac disease. *J Pediatr* 1974;**85**:527–9.
- Sires JM, de Majo SF. Diabetes and coeliac disease in children. *Pediatr Adolesc Endocr* 1977;**2**:227–33.
- Maki M, Hallstrom O, Huupponen T, *et al.* Increased prevalence of coeliac disease in diabetes. *Arch Dis Child* 1984;**59**:739–42.
- Savilahti E, Simell O, Koskimies S, *et al.* Coeliac disease in insulin-dependent diabetes mellitus. *J Pediatr* 1986;**108**:690–3.
- Cacciari E, Salardi S, Volta U, *et al.* Prevalence and characteristics of coeliac disease in type 1 diabetes mellitus. *Acta Paediatr Scand* 1987;**76**:671–2.
- Koletzko S, Burgin-Wolff A, Koletzko B, *et al.* Prevalence of coeliac disease in diabetic children and adolescents. A multicentre study. *Eur J Pediatr* 1988;**148**:113–17.
- Barera G, Bianchi C, Calisti L, *et al.* Screening of diabetic children for coeliac disease with antigliadin antibodies and HLA typing. *Arch Dis Child* 1991;**66**:491–4.
- Gadd S, Kamath KR, Silink M, *et al.* Co-existence of coeliac disease and insulin-dependent diabetes mellitus in children: screening sera using an ELISA test for gliadin antibody. *Aust N Z J Med* 1992;**22**:256–60.
- Sigurs N, Johansson C, Elfstrand PO, *et al.* Prevalence of coeliac disease in diabetic children and adolescents in Sweden. *Acta Paediatr* 1993;**82**:748–51.
- Rossi TM, Albini CH, Kumar V. Incidence of coeliac disease identified by the presence of serum endomysial antibodies in children with chronic diarrhoea, short stature, or insulin-dependent diabetes mellitus. *J Pediatr* 1993;**123**:262–4.
- Verge CF, Howard NJ, Rowley MJ, *et al.* Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: a population-based study. *Diabetologia* 1994;**37**:1113–20.
- Saukkonen T, Savilahti E, Reijonen H, *et al.* Coeliac disease: frequent occurrence after clinical onset of insulin-dependent diabetes mellitus. Childhood Diabetes in Finland Study Group. *Diabet Med* 1996;**13**:464–70.
- Lorini R, Scotta MS, Cortona L, *et al.* Coeliac disease and type 1 (insulin-dependent) diabetes mellitus in childhood: follow-up study. *J Diabetes Complications* 1996;**10**:154–9.
- Lorini R, Scaramuzza A, Vitali L, *et al.* Clinical aspects of coeliac disease in children with insulin-dependent diabetes mellitus. *J Pediatr Endocrinol Metab* 1996;**9**(suppl 1):101–11.
- Boudraa G, Hachlaf W, Benbouabdellah M, *et al.* Prevalence of coeliac disease in diabetic children and their first-degree relatives in west Algeria: screening with serological markers. *Acta Paediatr Suppl* 1996;**412**:58–60.
- Calero P, Ribes-Koninckx C, Albiach V, *et al.* IgA anti-gliadin antibodies as a screening method for nonovert coeliac disease in children with insulin-dependent diabetes mellitus. *J Pediatr Gastroenterol Nutr* 1996;**23**:29–33.
- Cacciari E, Bianchi FB, Salardi S, *et al.* Late development of IgA anti-endomysial antibodies and small intestinal mucosal atrophy after insulin dependent diabetes mellitus onset. *Arch Dis Child* 1997;**77**:465.
- Fraser-Reynolds KA, Butzner JD, Stephure DK, *et al.* Use of immunoglobulin A-anti-endomysial antibody to screen for coeliac disease in North American children with type 1 diabetes. *Diabetes Care* 1998;**21**:1985–9.
- Acerini CL, Ahmed ML, Ross KM, *et al.* Coeliac disease in children and adolescents with IDDM: clinical characteristics and response to gluten-free diet. *Diabet Med* 1998;**15**:38–44.
- Vitoria JC, Castano L, Rica I, *et al.* Association of insulin-dependent diabetes mellitus and coeliac disease: a study based on serologic markers. *J Pediatr Gastroenterol Nutr* 1998;**27**:47–52.
- Roldan MB, Barrio R, Roy G, *et al.* Diagnostic value of serological markers for coeliac disease in diabetic children and adolescents. *J Pediatr Endocrinol Metab* 1998;**11**:751–6.
- Carlsson AK, Axelsson IE, Borulf SK, *et al.* Prevalence of IgA-anti-endomysium and IgA-anti-gliadin autoantibodies at diagnosis of insulin-dependent diabetes mellitus in Swedish children and adolescents. *Pediatrics* 1999;**103**:1248–52.
- Schober E, Bittmann B, Granditsch G, *et al.* Screening by anti-endomysium antibody for coeliac disease in diabetic children and adolescents in Austria. *J Pediatr Gastroenterol Nutr* 2000;**30**:391–6.
- Kordonouri O, Dieterich W, Schuppan D, *et al.* Autoantibodies to tissue transglutaminase are sensitive serological parameters for detecting silent coeliac disease in patients with type 1 diabetes mellitus. *Diabet Med* 2000;**17**:441–4.
- Gillett PM, Gillett HR, Israel DM, *et al.* High prevalence of coeliac disease in patients with type 1 diabetes detected by antibodies to endomysium and tissue transglutaminase. *Can J Gastroenterol* 2001;**15**:297–301.
- Aktay AN, Lee PC, Kumar V, *et al.* The prevalence and clinical characteristics of coeliac disease in juvenile diabetes in Wisconsin. *J Pediatr Gastroenterol Nutr* 2001;**33**:462–5.
- Hansen D, Bennedbaek FN, Hansen LK, *et al.* High prevalence of coeliac disease in Danish children with type 1 diabetes mellitus. *Acta Paediatr* 2001;**90**:1238–43.
- Barera G, Bonfanti R, Viscardi M, *et al.* Occurrence of coeliac disease after onset of type 1 diabetes: a 6-year prospective longitudinal study. *Pediatrics* 2002;**109**:833–8.
- Catassi C, Ratsch IM, Gandolfi L, *et al.* Why is coeliac disease endemic in the people of the Sahara? *Lancet* 1999;**354**:647–8.
- Galli-Tsinopoulou A, Nousia-Arvanitakis S, Dracoulacos D, *et al.* Autoantibodies predicting diabetes mellitus type 1 in coeliac disease. *Horm Res* 1999;**52**:119–24.
- Pococco M, Ventura A. Coeliac disease and insulin-dependent diabetes mellitus: a causal association? *Acta Paediatr* 1995;**84**:1432–3.
- Westman E, Ambler GR, Royle M, *et al.* Children with coeliac disease and insulin dependent diabetes mellitus—growth, diabetes control and dietary intake. *J Pediatr Endocrinol Metab* 1999;**12**:433–42.
- Lorini R, Maggiore G, De Giacomo C, *et al.* Elevated serum aminotransferase activity: an early manifestation of gluten-sensitive enteropathy in children with insulin-dependent diabetes mellitus. *J Pediatr* 1994;**124**:995.
- Iafusco D, Rea F, Prisco F. Hypoglycemia and reduction of the insulin requirement as a sign of coeliac disease in children with IDDM. *Diabetes Care* 1998;**21**:1379–81.
- Holmes GKT. Non-malignant complications of coeliac disease. *Acta Paediatr Suppl* 1996;**412**:68–75.
- Holmes GKT, Prior P, Lane MR, *et al.* Malignancy in coeliac disease—effect of a gluten free diet. *Gut* 1989;**30**:333–8.
- Schweizer JJ, Oren A, Mearin ML. Cancer in children with coeliac disease: a survey of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr Gastroenterol Nutr* 2001;**33**:97–100.
- Freeman HJ, Chiu BK. Multifocal small bowel lymphoma and latent coeliac sprue. *Gastroenterology* 1986;**90**:1992–7.
- Natazuka T, Manabe Y, Kono M, *et al.* Association between non-insulin dependent diabetes mellitus and non-Hodgkin's lymphoma. *BMJ* 1994;**309**:1269.
- Brody JI. Non-insulin dependent diabetes mellitus and non-Hodgkin's lymphoma. Already reported. *BMJ* 1995;**310**:1009.
- Cerhan JR, Wallace RB, Folsom AR, *et al.* Medical history risk factors for non-Hodgkin's lymphoma in older women. *J Natl Cancer Inst* 1997;**89**:314–18.
- Zahm SH, Blair A, Cantor KP, *et al.* Non-insulin dependent diabetes mellitus and non-Hodgkin's lymphoma. Other American studies fail to confirm an association. *BMJ* 1995;**310**:1009–10.
- O'Connor TM, Cronin CC, Loane JF, *et al.* Type 1 diabetes mellitus, coeliac disease, and lymphoma: a report of four cases. *Diabet Med* 1999;**16**:614–17.
- Forst T, Pflutzner A, Kann P, *et al.* Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. *Diabet Med* 1995;**12**:874–9.
- Tuominen JT, Impivaara O, Puukka P, *et al.* Bone mineral density in patients with type 1 and type 2 diabetes. *Diabetes Care* 1999;**22**:1196–200.
- Lunt H, Florkowski CM, Cook HB, *et al.* Bone mineral density, type 1 diabetes, and coeliac disease. *Diabetes Care* 2001;**24**:1791–2.
- Ventura A, Magazzu G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with coeliac disease. SIGEP